HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 354-363

  Lebeau, A ^a   Deimling, D ^a   Kaltz, C ^a   Sendelhofert, A ^a   Iff, A ^a   Luthardt, B ^a   Untch, M ^a   Lohrs U ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0035863284     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.354     Document Type: Article

References (37)

1. ERBB2 oncogene in human breast cancer and its clinical significance
2. HER-2/neu (c-erb-B2) gene and protein in breast cancer
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
5. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
6. Quantitation of HER-2/neu and c-myc gene amplification in human breast cancer archival material using fluorescence in situ hybridization
7. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
8. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
9. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxoruhicin against HER2/neu overexpressing human breast cancer xenografts
10. Antibody dependant cell-mediated cytotoxicity in breast cancer patients in phase III clinical trials of a humanized anti-HER2 antibody
11. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
12. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
13. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
14. Increased HER2 with U.S. Food and Drug Administration-approved antibody
15. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
16. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
17. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers
18. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization in the Herceptin pivotal trials
19. Pathological prognostic factors in breast cancer: Experience from a large study with long-term follow-up
20. Oncogene activations in human breast cancer
21. NCL-CBI1, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene effective for use on formalin-fixed, paraffin-embedded tissue
22. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
23. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues
24. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry
25. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies
26. C-erbB-2 immunostaining: Problems with interpretation
27. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
28. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone
29. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
30. The molecular biology of HER-2
31. HER-2 overexpression, and intratumor heterogeneity in human breast cancer
32. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples
33. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
34. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
35. Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
36. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer
37. First-line, nonhormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)